2015

Pharmaceutical and device manufacturers operating in France must brace for more extensive reporting requirements under…

Last week, in our Vermont transparency update, we wrote that Vermont’s Attorney General enforced the state’s Prescribed…

Pharmaceutical and device companies often bear the brunt of the kickback enforcement in the United States. The Anti-Kickback…

According to America Speaks, a compilation of public opinion polls commissioned by Research!America, the majority of Americans…

 Celltrion will have to wait longer than expected for FDA's Advisory Committee to review its application for Remsima, a …

An interesting claim against the pharmaceutical industry (though usually made by only industry's most hardened critics) is that…

In the last few months, Vermont’s Attorney General's Office has been busier than usual regarding its Prescribed Product…

Earlier this month, Minnesota-based ev3 agreed to pay $1.25 million to the Department of Justice to settle False Claims…

The market research space is an interesting one as far as Sunshine reporting is concerned because it implicates many of…

Recognizing that drug companies would actually incur a financial loss in developing important drugs for rare conditions,…